Marianne J Hjermstad, Gunnhild Jakobsen, Jann Arends, Trude Balstad, Leo R Brown, Asta Bye, Andrew J S Coats, Olav F Dajani, Ross D Dolan, Marie T Fallon, Christine Greil, Alexandra Grzyb, Stein Kaasa, Lisa H Koteng, Anne M May, James McDonald, Inger Ottestad, Iain Philips, Eric J Roeland, Judith Sayers, Melanie R Simpson, Richard J E Skipworth, Tora S Solheim, Mariana S Sousa, Ola M Vagnildhaug, Barry J A Laird
The use of patient-reported outcomes (PROMs) of quality of life (QOL) is common in cachexia trials. Patients' self-report on health, functioning, wellbeing, and perceptions of care, represent important measures of efficacy. This review describes the frequency, variety, and reporting of QOL endpoints used in cancer cachexia clinical trials. Electronic literature searches were performed in Medline, Embase, and Cochrane (1990-2023). Seven thousand four hundred thirty-five papers were retained for evaluation. Eligibility criteria included QOL as a study endpoint using validated measures, controlled design, adults (>18 years), ≥40 participants randomized, and intervention exceeding 2 weeks...
March 29, 2024: Journal of Cachexia, Sarcopenia and Muscle